Fisetin and Reduced Matrix Metalloproteinase-2 Level

• Fisetin Prolongs Therapy Window of Brain Ischemic Stroke Using Tissue Plasminogen Activator: A Double-Blind Randomized Placebo-Controlled Clinical Trial.

  • 2019-01-01
  • RCT
  • Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 25
  • • Limin Wang
    • Di Cao
    • Huijun Wu
    • Hongning Jia
    • Chaoping Yang
    • Lihua Zhang

  • PubMed: 31434498
  • DOI: 10.1177/1076029619871359

  4 Insights on

  • Reduced Matrix Metalloproteinase-2 Level

  • High evidence
  • Clinical

  The beneficial effect of fisetin was likely attributable to reduced levels of MMP-2, MMP-9, and CRP in the serum

  Effect

  Beneficial

  Effect size

  Small

  Significant

  Yes